Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts

Capmatinib is an oral, ATP‐competitive, and highly potent, type 1b MET inhibitor. Herein, we report phase 1 dose‐escalation results for capmatinib in advanced MET‐positive solid tumor patients and dose expansion in advanced non‐lung tumors. Capmatinib was well tolerated with a manageable safety prof...

Descripción completa

Detalles Bibliográficos
Autores principales: Bang, Yung‐Jue, Su, Wu‐Chou, Schuler, Martin, Nam, Do‐Hyun, Lim, Wan Teck, Bauer, Todd M., Azaro, Analia, Poon, Ronnie Tung Ping, Hong, David, Lin, Chia‐Chi, Akimov, Mikhail, Ghebremariam, Samson, Zhao, Sylvia, Giovannini, Monica, Ma, Brigette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004521/
https://www.ncbi.nlm.nih.gov/pubmed/31778267
http://dx.doi.org/10.1111/cas.14254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004521/
https://www.ncbi.nlm.nih.gov/pubmed/31778267
http://dx.doi.org/10.1111/cas.14254

Ejemplares similares